Global Nuclear Medicine (Medical Isotopes/ Radioisotopes/ Radiopharmaceuticals) Market in PET/SPECT Imaging and Therapy - Competitive Landscape, Current trends and Forecasts (2010 – 2015)

Report Summary

Radiopharmaceuticals Therapy and PET/SPECT Imaging – A Global Scenario (2010-2015)

Radiopharmaceuticals are pharmaceutical agents used to diagnose certain medical problems such as cardiac, cancer, neurology, and/or treat certain conditions such as cancers. The use of radiopharmaceuticals as tracer dates back to 1930’s. Over the years, technical advancement in production, diagnostic equipments (SPECT and PET), and discovery of new radiopharmaceutical have driven the market. The global radiopharmaceuticals market for therapy and PET & SPECT imaging was valued at $3,213 million in 2010 and is expected to reach $4,734 million by 2015; growing at a CAGR of 8.1% from 2010 to 2015. The PET & SPECT diagnosis accounted for the largest share -90%- of the global radiopharmaceutical market.

Diagnostic applications of radiopharmaceuticals have around 90% of the market share. The market is growing due to the increasing incidences of cancer and cardiac diseases, requisition of better imaging techniques for diseases such as Alzheimer’s. Targeted alpha therapy is one of the most promising treatments for cancer, which is being researched upon by cancer institutes.

Driven by the increasing incidence of cardiac and cancer diseases, early and accurate diagnosis, increasing awareness amongst the masses, and expanding application segment; the global radiopharmaceutical market reached around $3.2 billion in 2010. Radiopharmaceuticals are used for the diagnosis and treatment of various ailments such as cancer, cardiac, renal, and respiratory diseases among the others. PET machines enable radiologists in early detection of cancer, cardiac, and Alzheimer’s disease among the patients. This would increase the demand for PET machines among the healthcare centers and providers. Similarly, SPECT scanners have been on the forefront to bring about significant changes in the diagnostic imaging equipment landscape with opportunities in the market for neuroendocrine tumor imaging. For diagnostic applications of radiopharmaceuticals, radioisotopes such as FDG for PET and technetium for SPECT are most commonly used.

PET and SPECT scans provide dynamic images of the body’s interior, rather than just the bones, like X-ray and magnetic resonance imaging (MRI). PET scan lets the doctor identify glucose metabolism in different parts of the body in a patient. Cancer cells grow at a faster rate than the other cells. The machine detects the speed of glucose being used and indicates the presence of cancerous tumors. The cancerous cell breaks down glucose at a higher rate than the other cells and this increased activity can be seen in a scan. Thus, the use of PET and SPECT scans facilitates early and accurate diagnosis of diseases such as cancer. Increased usage of PET & SPECT scans in turn increases the demand for radiopharmaceuticals.

FDG is the major radiopharmaceutical used in PET (approximately 90%). PET procedures are preferred over SPECT as PET is more accurate, sensitive, and endowed with better spatial arrangement of the image. Besides, the main radiopharmaceutical used in SPECT; i.e. technetium (99m) has a limited supply, forcing people to look for alternatives. FDG can be produced at desired levels to meet all the imaging requirements. This situation is boosting the FDG market.

Most of the radiopharmaceuticals are used in hospitals; accounting for 92%. Majority of the radiopharmaceuticals are administered intravenously. The market for radiopharmaceuticals is restricted by their high cost and difficulties faced while transporting them.

Scope of the report

This research report categorizes the radiopharmaceuticals therapy and PET/SPECT imaging market on the basis of isotopes, routes of administration, applications, and geography; forecasting revenue, and analyzing trends in each of the following submarkets:

On the basis of isotopes:

Fludeoxyglucose (F18), Technetium (Tc99m), Gallium (Ga67), Sodium Iodide (I123), Iobenguane (I131), Rhenium (Re186), Samarium (Sm153),Thallium (Tl201), Yttrium (Y90), Erbium(Er169), and others

On the basis of routes of administration:
Intravenous, peroral, inhalation, and others

On the basis of applications:

Diagnosis (PET and SPECT), indication for diagnosis, and therapy
On the basis of geography:
North America (U.S. and Canada), Europe, Asia-Pacific, Japan, and Rest of the World

Each section provides market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments. In addition, the report provides more than 16 company profiles covering all the sub-segments

Table Of Contents

EXECUTIVE SUMMARY

MARKET SCENARIO

1 INTRODUCTION
1.1KEY TAKE-AWAYS
1.2REPORT DESCRIPTION
1.3MARKETS COVERED
1.4STAKEHOLDERS
1.5RESEARCH METHODOLOGY

2 SUMMARY

3 MARKET OVERVIEW
3.1DEFINITION OF RADIOPHARMACEUTICALS
3.2EVOLUTION
3.3MARKET SEGMENTATION
3.4DRIVING FORCE ANALYSIS
3.4.1DRIVERS
3.4.1.1Increasing incidence of cancer and cardiac ailments
3.4.1.2Increasing use of SPECT and PET scans
3.4.1.3Rising awareness of Radiopharmaceuticals among physicians
3.4.1.4Alpha radioimmunotherapy-based targeted cancer treatment
3.4.1.5Ready availability of radiopharmaceuticals from cyclotrons
3.4.2RESTRAINTS
3.4.2.1Half-life of radiopharmaceuticals
3.4.2.2High capital demand
3.4.2.3Lack of good manufacturing practices (GMP)
3.4.2.4Inefficient effluent treatment management
3.4.2.5Stringent regulatory guidelines
3.4.3THREAT
3.4.3.1Shutdown of nuclear reactors impacts the production of radioisotopes
3.4.4OPPORTUNITIES
3.4.4.1Increasing demand for diagnosis
3.4.4.2High demand in geographies with inadequate supply
3.5WINNING IMPERATIVES
3.5.1INTRODUCTION OF NEW AGENTS FOR THE TREATMENT OF ALZHEIMER’S DISEASE
3.5.2INCREASING REGULATORY APPROVALS OF RADIOPHARMACEUTICALS
3.6BURNING ISSUES
3.6.1HIGH COST OF IMAGING DEVICES
3.6.2SHORTAGE IN SUPPLY OF TECHNETIUM-99M (RADIOISOTOPE)
3.7MARKET SHARE ANALYSIS
3.8END-USER ANALYSIS
3.9COMPETITIVE ANALYSIS
3.10PATENT ANALYSIS
3.11FUTURE RADIOPHARMACEUTICALS

4 RADIOPHARMACEUTICAL MARKET, BY ISOTOPES
4.1INTRODUCTION
4.2FLUDEOXYGLUCOSE (18F)
4.2.1INCREASE IN AVAILABILITY OF HYBRID PET/CT MACHINES
4.2.2RISE IN PET PROCEDURES INCREASES DEMAND FOR FDG
4.2.3HIGH GENERATION COSTS OF FDG
4.2.4NEED FOR SPEEDY & EFFICIENT TRANSPORTATION
4.3TECHNETIUM (99MTC)
4.3.1TECHNETIUM CAN COMBINE WITH 31 DIFFERENT CARRIER MOLECULES
4.3.2LACK OF AVAILABILITY OF TECHNETIUM
4.4THALLIUM (201TL)
4.4.1THALLIUM MOST COMMON SUBSTITUTE OF TECHNETIUM
4.5GALLIUM (67GA)
4.6SODIUM IODIDE (123I)
4.7IOBENGUANE (131I)
4.8RHENIUM (186RE)
4.9SAMARIUM (153SM)
4.10YTTRIUM (90Y)
4.11ERBIUM (169ER)
4.12OTHERS

5 RADIOPHARMACEUTICAL MARKET, BY ROUTES OF ADMINISTRATION (ROA)
5.1INTRODUCTION
5.2INTRAVENOUS ADMINISTRATION
5.3INHALATION ADMINISTRATION
5.4PERORAL ADMINISTRATION
5.5OTHER ROUTES OF ADMINISTRATION

6 RADIOPHARMACEUTICAL MARKET, BY APPLICATIONS
6.1INTRODUCTION
6.2RADIOPHARMACEUTICALS FOR DIAGNOSIS
6.2.1SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) IMAGING
6.2.1.1Introduction
6.2.1.2Principle & procedure
6.2.1.3Radiotracers
6.2.1.4Limitations
6.2.1.5Safety
6.2.1.6Radiopharmaceuticals
6.2.1.6.1Technetium-99m
6.2.1.6.2Gallium (67Ga)
6.2.1.6.3Sodium iodide (123I)
6.2.1.6.4Iobenguane (131I)
6.2.1.6.5Rhenium (186Re)
6.2.1.6.6Thallium (201Tl)
6.2.1.6.7Yttrium (90Y)
6.2.1.6.8Others
6.2.2POSITRON EMISSION TOMOGRAPHY (PET) IMAGING
6.2.2.1Introduction
6.2.2.2Principle & procedure
6.2.2.3Radiotracers
6.2.2.4Limitations
6.2.2.5Safety
6.2.2.6Radiopharmaceuticals
6.2.2.6.118F-FD/Fluorodeoxyglucose (18F)
6.2.2.6.2Others
6.3RADIOPHARMACEUTICAL MARKET, BY INDICATION FOR DIAGNOSIS
6.3.1INTRODUCTION
6.3.2CARDIAC DISEASES
6.3.3NEUROIMAGING
6.3.4BONE SCAN
6.3.5LIVER SCAN
6.3.6RESPIRATORY SCAN
6.3.7RENAL SCAN
6.3.8THYROID SCAN
6.4RADIOPHARMACEUTICALS FOR TREATMENT/RADIONUCLIDE THERAPY (RNT)
6.4.1TARGETED ALPHA THERAPY (TAT) OR ALPHA RADIOIMMUNOTHERAPY
6.4.2RADIOPHARMACEUTICALS
6.4.2.1Iobenguane (131I)
6.4.2.2Rhenium (186Re)
6.4.2.3Samarium (153Sm)
6.4.2.4Erbium (Er169)
6.4.2.5Others

7 REGULATORY CHALLENGES FOR RADIOPHARMACEUTICALS PRODUCTION
7.1INTRODUCTION
7.2SAFETY OF PERSONNEL
7.3EQUIPMENT & FACILITY
7.4TRANSPORTATION GUIDELINES
7.5GUIDELINES IN EUROPE
7.6GUIDELINES IN U.S.
7.7REIMBURSEMENT

8 GEOGRAPHIC ANALYSIS (CONSUMPTION)
8.1INTRODUCTION
8.2NORTH AMERICA
8.2.1U.S.
8.2.2CANADA
8.3EUROPE
8.4APAC (EXCLUDING JAPAN)
8.5JAPAN
8.6REST OF THE WORLD (ROW)

9 GEOGRAPHIC ANALYSIS (PRODUCTION)
9.1INTRODUCTION
9.2NORTH AMERICA
9.3EUROPE
9.4APAC (EXCLUDING JAPAN)
9.5JAPAN
9.6REST OF THE WORLD

10 COMPETITIVE LANDSCAPE

11 COMPANY PROFILES
11.1AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO)
11.1.1OVERVIEW
11.1.2PRODUCTS & SERVICES
11.1.3FINANCIALS
11.1.4STRATEGY
11.1.5DEVELOPMENTS
11.2BOARD OF RADIATION AND ISOTOPE TECHNOLOGY (BRIT)
11.2.1OVERVIEW
11.2.2PRODUCTS & SERVICES
11.3CARDINAL HEALTH INC
11.3.1OVERVIEW
11.3.2PRODUCTS & SERVICES
11.3.3FINANCIALS
11.3.4STRATEGY
11.3.5DEVELOPMENTS
11.4COVIDIEN PLC
11.4.1OVERVIEW
11.4.2PRODUCTS & SERVICES
11.4.3FINANCIALS
11.4.4STRATEGY
11.4.5DEVELOPMENTS
11.5ECZACIBASI-MONROL
11.5.1OVERVIEW
11.5.2PRODUCTS & SERVICES
11.5.3STRATEGY
11.5.4FINANCIALS
11.5.5DEVELOPMENTS
11.6FUJIFILM HOLDINGS CORP
11.6.1OVERVIEW
11.6.2PRODUCTS & SERVICES
11.6.3FINANCIALS
11.6.4STRATEGY
11.6.5DEVELOPMENTS
11.7GE HEALTHCARE
11.7.1OVERVIEW
11.7.2PRODUCTS & SERVICES
11.7.3FINANCIALS
11.7.4STRATEGY
11.7.5DEVELOPMENTS
11.8IBA GROUP
11.8.1OVERVIEW
11.8.2PRODUCTS & SERVICES
11.8.3FINANCIALS
11.8.4STRATEGY
11.8.5DEVELOPMENTS
11.9INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE (POLATOM)
11.9.1OVERVIEW
11.9.2PRODUCTS & SERVICES
11.9.3STRATEGY
11.9.4DEVELOPMENTS
11.10INSTITUTE OF ISOTOPES CO. LTD.
11.10.1OVERVIEW
11.10.2PRODUCTS & SERVICES
11.10.3STRATEGY
11.11INSTITUTE OF RADIOELEMENT (IRE)
11.11.1OVERVIEW
11.11.2PRODUCTS & SERVICES
11.11.3STRATEGY
11.11.4DEVELOPMENTS
11.12LANTHEUS MEDICAL IMAGING INC
11.12.1OVERVIEW
11.12.2PRODUCTS & SERVICES
11.12.3FINANCIALS
11.12.4STRATEGY
11.12.5DEVELOPMENTS
11.13NORDION INC.
11.13.1OVERVIEW
11.13.2PRODUCTS & SERVICES
11.13.3FINANCIALS
11.13.4STRATEGY
11.13.5DEVELOPMENTS
11.14NTP RADIOISOTOPES (PTY) LTD
11.14.1OVERVIEW
11.14.2PRODUCTS & SERVICES
11.14.3FINANCIALS
11.14.4STRATEGY
11.14.5DEVELOPMENTS
11.15SAMYOUNG UNITECH CO. LTD
11.15.1OVERVIEW
11.15.2PRODUCTS & SERVICES
11.15.3FINANCIALS
11.15.4STRATEGY
11.16SIEMENS HEALTHCARE
11.16.1OVERVIEW
11.16.2PRODUCTS & SERVICES
11.16.3FINANCIALS
11.16.4STRATEGY
11.16.5DEVELOPMENTS

APPENDIX
U.S. PATENTS
EUROPE PATENTS
JAPAN PATENTS
WIPO PATENTS

List Of Tables

TABLE 1GLOBAL RADIOPHARMACEUTICAL MARKET REVENUE,
BY APPLICATIONS, 2008 – 2015 ($MILLION)
TABLE 2RADIOPHARMACEUTICAL MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($MILLION)
TABLE 3RADIOPHARMACEUTICALS IN CLINICAL TRIALS
TABLE 4RADIOPHARMACEUTICALS SEGMENTATION
TABLE 5GLOBAL RADIOPHARMACEUTICALS MARKET REVENUE, BY TYPES,
2008 – 2015 ($THOUSAND)
TABLE 6RADIOPHARMACEUTICALS MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($MILLION)
TABLE 7NORTH AMERICA: RADIOPHARMACEUTICAL MARKET REVENUE,
BY COUNTRIES, 2008 – 2015 ($MILLION)
TABLE 8FDG MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND)
TABLE 9NORTH AMERICA: FDG MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 10INDICATIONS DIAGNOSED BY TECHNETIUM
TABLE 11TECHNETIUM MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 12NORTH AMERICA: TECHNETIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND)
TABLE 13THALLIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND)
TABLE 14NORTH AMERICA: THALLIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 15GALLIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND)
TABLE 16NORTH AMERICA: GALLIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 17SODIUM IODIDE MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 18NORTH AMERICA: SODIUM IODIDE MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND)
TABLE 19IOBENGUANE MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 20NORTH AMERICA: IOBENGUANE MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND)
TABLE 21RHENIUM MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 22NORTH AMERICA: RHENIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 23SAMARIUM MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 24NORTH AMERICA: SAMARIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 25YTTRIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND)
TABLE 26NORTH AMERICA: YTTRIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 27ERBIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND)
TABLE 28NORTH AMERICA: ERBIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 29OTHERS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND)
TABLE 30NORTH AMERICA: OTHERS MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 31GLOBAL RADIOPHARMACEUTICALS ROUTE OF ADMINISTRATION MARKET REVENUE, BY TYPES, 2008 – 2015 ($MILLION)
TABLE 32RADIOPHARMACEUTICALS ROUTE OF ADMINISTRATION MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 33NORTH AMERICA: RADIOPHARMACEUTICALS ROUTE OF ADMINISTRATION MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($MILLION)
TABLE 34INTRAVENOUS ROUTE OF ADMINISTRATION MARKET REVENUE,
BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 35NORTH AMERICA: INTRAVENOUS ROUTE OF ADMINISTRATION MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($MILLION)
TABLE 36INHALATION ROUTE OF ADMINISTRATION MARKET REVENUE,
BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 37NORTH AMERICA: INHALATION ROUTE OF ADMINISTRATION MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($MILLION)
TABLE 38PERORAL ROUTE OF ADMINISTRATION MARKET REVENUE,
BY GEOGRAPHY, 2008 – 2015 ($THOUSAND)
TABLE 39NORTH AMERICA: PERORAL ROUTE OF ADMINISTRATION MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND)
TABLE 40OTHER TYPES OF ROUTES OF ADMINISTRATION
TABLE 41OTHER ROUTES OF ADMINISTRATION MARKET REVENUE,
BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 42NORTH AMERICA: OTHER ROUTES OF ADMINISTRATION MARKET,
BY COUNTRIES, 2008 – 2015 ($MILLION)
TABLE 43GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET REVENUE,
BY TYPES, 2008 – 2015 ($MILLION)
TABLE 44DIAGNOSTIC RADIOPHARMACEUTICALS MARKET REVENUE,
BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 45NORTH AMERICA: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY COUNTRIES, 2008 – 2015 ($MILLION)
TABLE 46GLOBAL SPECT RADIOPHARMACEUTICALS MARKET, BY TYPES,
2008 – 2015 ($THOUSAND)
TABLE 47SPECT RADIOPHARMACEUTICALS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 48NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($MILLION)
TABLE 49TECHNETIUM MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 50NORTH AMERICA: TECHNETIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND)
TABLE 51GALLIUM MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 52NORTH AMERICA: GALLIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 53SODIUM IODIDE MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 54NORTH AMERICA: SODIUM IODIDE MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND)
TABLE 55IOBENGUANE MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 56NORTH AMERICA: IOBENGUANE MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND)
TABLE 57RHENIUM MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 58NORTH AMERICA: RHENIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 59THALLIUM MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 60NORTH AMERICA: THALLIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 61YTTRIUM MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 62NORTH AMERICA: YTTRIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 63OTHERS MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 64NORTH AMERICA: OTHERS MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 65GLOBAL PET RADIOPHARMACEUTICALS MARKET REVENUE,
BY TYPES, 2008 – 2015 ($MILLION)
TABLE 66PET RADIOPHARMACEUTICALS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 67NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET,
BY COUNTRIES, 2008 – 2015 ($MILLION)
TABLE 68FDG MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND)
TABLE 69NORTH AMERICA: FDG MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 70OTHERS MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 71NORTH AMERICA: OTHERS MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 72TREATMENT RADIOPHARMACEUTICALS MARKET REVENUE,
BY TYPES, 2008 – 2015 ($THOUSAND)
TABLE 73TREATMENT RADIOPHARMACEUTICALS MARKET REVENUE,
BY GEOGRAPHY, 2008 – 2015 ($THOUSAND)
TABLE 74NORTH AMERICA: TREATMENT RADIOPHARMACEUTICALS MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND)
TABLE 75IOBENGUANE MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND)
TABLE 76NORTH AMERICA: IOBENGUANE MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND)
TABLE 77RHENIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND)
TABLE 78NORTH AMERICA: RHENIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 79SAMARIUM MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 80NORTH AMERICA: SAMARIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 81ERBIUM MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 82NORTH AMERICA ERBIUM MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 83OTHER RADIOPHARMACEUTICALS, BY TYPES
TABLE 84OTHERS MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($THOUSAND)
TABLE 85NORTH AMERICA: OTHERS MARKET REVENUE, BY COUNTRIES,
2008 – 2015 ($THOUSAND)
TABLE 86NORTH AMERICA: RADIOPHARMACEUTICALS MARKET REVENUE,
BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND)
TABLE 87U.S: RADIOPHARMACEUTICALS MARKET REVENUE,
BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND)
TABLE 88CANADA: RADIOPHARMACEUTICALS MARKET REVENUE,
BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND)
TABLE 89EUROPE: RADIOPHARMACEUTICALS MARKET REVENUE,
BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND)
TABLE 90APAC: RADIOPHARMACEUTICALS MARKET REVENUE,
BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND)
TABLE 91JAPAN: RADIOPHARMACEUTICALS MARKET REVENUE,
BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND)
TABLE 92ROW: RADIOPHARMACEUTICALS MARKET REVENUE,
BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND)
TABLE 93MERGERS & ACQUISITIONS
TABLE 94AGREEMENTS & COLLABORATIONS
TABLE 95NEW PRODUCT DEVELOPMENT
TABLE 96NEW EXPANSION FACILITIES
TABLE 97APPROVALS
TABLE 98ANSTO HEALTH: MARKET REVENUE, 2008 – 2010 ($MILLION)
TABLE 99CARDINAL: MARKET REVENUE, 2008 – 2010 ($MILLION)
TABLE 100CARDINAL: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 101COVIDIEN: MARKET SALES AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 102COVIDIEN: MARKET SALES, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 103COVIDIEN: MARKET REVENUE, BY SEGMENT, 2008 – 2010 ($MILLION)
TABLE 104COVIDIEN: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 105FUJIFILM: MARKET REVENUE, 2009 – 2011 ($MILLION)
TABLE 106FUJIFILM: MARKET REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 107FUJIFILM: MEDICAL SYSTEM SEGMENT REVENUE,
2009 – 2011 ($MILLION)
TABLE 108FUJIFILM: MARKET REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 109GE HEALTHCARE: MARKET REVENUE AND R&D EXPENSES,
2007 – 2009 ($BILLION)
TABLE 110GE HEALTHCARE: MARKET REVENUE, BY SEGMENT,
2007 – 2009 ($BILLION)
TABLE 111GE HEALTHCARE: MARKET REVENUE, BY GEOGRAPHY,
2007 – 2009 ($BILLION)
TABLE 112IBA GROUP: TOTAL MARKET REVENUE, 2008 – 2010 ($MILLION)
TABLE 113IBA GROUP: MARKET REVENUE, BY SEGMENTS,
2008 – 2010 ($MILLION)
TABLE 114IBA GROUP: MARKET REVENUE, BY GEOGRAPHY,
2008 – 2010 ($MILLION)
TABLE 115LANTHEUS: MARKET REVENUE AND R&D EXPENSES,
2008 – 2010 ($THOUSAND)
TABLE 116LANTHEUS: MARKET REVENUE, BY SEGMENTS,
2008 – 2010 ($THOUSAND)
TABLE 117LANTHEUS: MARKET REVENUE, BY GEOGRAPHY,
2008 – 2010 ($THOUSAND)
TABLE 118NORDION: MARKET REVENUE AND R&D EXPENSES,
2008 – 2010 ($MILLION)
TABLE 119NORDION: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 120NORDION: MARKET REVENUE, BY COUNTRIES,
2008 – 2010 ($MILLION)
TABLE 121SIEMENS HEALTHCARE: TOTAL MARKET REVENUE,
2008 – 2010 ($MILLION)
TABLE 122SIEMENS HEALTHCARE: MARKET REVENUE, BY SEGMENTS,
2008 – 2010 ($MILLION)

List Of Figures

FIGURE 1RADIOPHARMACEUTICAL MARKET, BY RADIOISOTOPES, 2008 – 2015
FIGURE 2EVOLUTION IN RADIOPHARMACEUTICALS
FIGURE 3RADIOPHARMACEUTICALS: MARKET SEGMENTATION
FIGURE 4FACTORS DRIVING THE RADIOPHARMACEUTICALS MARKET
FIGURE 5RADIOPHARMACEUTICAL MARKET SHARE ANALYSIS, 2010
FIGURE 6ANALYSIS OF RADIOPHARMACEUTICALS MARKET, BY END-USERS, 2010
FIGURE 7COMPETITIVE LANDSCAPE FOR RADIOPHARMACEUTICALS MARKET
FIGURE 8PATENT ANALYSIS, BY ASSIGNEE, 2005 – 2010
FIGURE 9GLOBAL RADIOPHARMACEUTICALS MARKET SHARE, BY PRODUCTION
FIGURE 10GLOBAL RADIOPHARMACEUTICALS MARKET: COMPETITIVE LANDSCAPE